The University of Chicago Header Logo

Connection

Kenneth S. Polonsky to Adult

This is a "connection" page, showing publications Kenneth S. Polonsky has written about Adult.
Connection Strength

0.504
  1. Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes. Diabetes. 2012 Jul; 61(7):1793-800.
    View in: PubMed
    Score: 0.028
  2. Kir6.2 variant E23K increases ATP-sensitive K+ channel activity and is associated with impaired insulin release and enhanced insulin sensitivity in adults with normal glucose tolerance. Diabetes. 2009 Aug; 58(8):1869-78.
    View in: PubMed
    Score: 0.023
  3. Impaired beta-cell compensation to dexamethasone-induced hyperglycemia in women with polycystic ovary syndrome. Am J Physiol Endocrinol Metab. 2004 Aug; 287(2):E241-6.
    View in: PubMed
    Score: 0.015
  4. Insulin secretory responses to rising and falling glucose concentrations are delayed in subjects with impaired glucose tolerance. Diabetologia. 2002 Apr; 45(4):509-17.
    View in: PubMed
    Score: 0.014
  5. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med. 2001 Sep 27; 345(13):971-80.
    View in: PubMed
    Score: 0.013
  6. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest. 1997 Aug 01; 100(3):530-7.
    View in: PubMed
    Score: 0.010
  7. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997 Jul; 82(7):2108-16.
    View in: PubMed
    Score: 0.010
  8. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997 Feb; 82(2):524-30.
    View in: PubMed
    Score: 0.010
  9. Altered insulin secretory responses to glucose in diabetic and nondiabetic subjects with mutations in the diabetes susceptibility gene MODY3 on chromosome 12. Diabetes. 1996 Nov; 45(11):1503-10.
    View in: PubMed
    Score: 0.009
  10. Elevated plasma glucose 2 h postchallenge predicts defects in beta-cell function. Am J Physiol. 1996 Apr; 270(4 Pt 1):E572-9.
    View in: PubMed
    Score: 0.009
  11. Insulin secretion in insulin-resistant women with a history of gestational diabetes. Metabolism. 1995 Aug; 44(8):1067-73.
    View in: PubMed
    Score: 0.009
  12. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest. 1995 Jul; 96(1):520-7.
    View in: PubMed
    Score: 0.009
  13. Altered insulin secretory responses to glucose in subjects with a mutation in the MODY1 gene on chromosome 20. Diabetes. 1995 Jun; 44(6):699-704.
    View in: PubMed
    Score: 0.009
  14. Lilly Lecture 1994. The beta-cell in diabetes: from molecular genetics to clinical research. Diabetes. 1995 Jun; 44(6):705-17.
    View in: PubMed
    Score: 0.009
  15. Alterations in the patterns of insulin secretion before and after diagnosis of IDDM. Diabetes Care. 1995 Apr; 18(4):568-71.
    View in: PubMed
    Score: 0.008
  16. Insulin secretion and clearance during low-dose graded glucose infusion. Am J Physiol. 1995 Jan; 268(1 Pt 1):E21-7.
    View in: PubMed
    Score: 0.008
  17. Compensation in pancreatic beta-cell function in subjects with glucokinase mutations. Diabetes. 1994 May; 43(5):718-23.
    View in: PubMed
    Score: 0.008
  18. Xenin-25 delays gastric emptying and reduces postprandial glucose levels in humans with and without type 2 diabetes. Am J Physiol Gastrointest Liver Physiol. 2014 Feb 15; 306(4):G301-9.
    View in: PubMed
    Score: 0.008
  19. Quantitative evaluation of the effect of low-intensity exercise on insulin secretion in man. Metabolism. 1993 Jul; 42(7):829-33.
    View in: PubMed
    Score: 0.008
  20. Oscillatory insulin secretion after pancreas transplant. Diabetes. 1993 Jun; 42(6):855-61.
    View in: PubMed
    Score: 0.007
  21. Defects in beta-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab. 1993 May; 76(5):1241-7.
    View in: PubMed
    Score: 0.007
  22. Analytical problems in detecting rapid insulin secretory pulses in normal humans. Am J Physiol. 1993 Feb; 264(2 Pt 1):E231-8.
    View in: PubMed
    Score: 0.007
  23. Alterations in the kinetics of C-peptide and insulin secretion in hyperthyroidism. J Clin Endocrinol Metab. 1993 Jan; 76(1):79-84.
    View in: PubMed
    Score: 0.007
  24. A practical approach to fasting hypoglycemia. N Engl J Med. 1992 Apr 09; 326(15):1020-1.
    View in: PubMed
    Score: 0.007
  25. Circadian modulation of glucose and insulin responses to meals: relationship to cortisol rhythm. Am J Physiol. 1992 Apr; 262(4 Pt 1):E467-75.
    View in: PubMed
    Score: 0.007
  26. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes. 1992 Mar; 41(3):368-77.
    View in: PubMed
    Score: 0.007
  27. Moderate effect of duodenal-jejunal bypass surgery on glucose homeostasis in patients with type 2 diabetes. Obesity (Silver Spring). 2012 Jun; 20(6):1266-72.
    View in: PubMed
    Score: 0.007
  28. Modulation of glucose regulation and insulin secretion by circadian rhythmicity and sleep. J Clin Invest. 1991 Sep; 88(3):934-42.
    View in: PubMed
    Score: 0.007
  29. Postprandial triglyceride response in type 1 (insulin-dependent) diabetes mellitus is not altered by short-term deterioration in glycaemic control or level of postprandial insulin replacement. Diabetologia. 1991 Apr; 34(4):253-9.
    View in: PubMed
    Score: 0.006
  30. Ginseng and ginsenoside Re do not improve ß-cell function or insulin sensitivity in overweight and obese subjects with impaired glucose tolerance or diabetes. Diabetes Care. 2011 May; 34(5):1071-6.
    View in: PubMed
    Score: 0.006
  31. Entrainment of pulsatile insulin secretion by oscillatory glucose infusion. J Clin Invest. 1991 Feb; 87(2):439-45.
    View in: PubMed
    Score: 0.006
  32. Postprandial lipoprotein metabolism in normal and obese subjects: comparison after the vitamin A fat-loading test. J Clin Endocrinol Metab. 1990 Oct; 71(4):1041-50.
    View in: PubMed
    Score: 0.006
  33. Lack of effect of high-dose biosynthetic human C-peptide on pancreatic hormone release in normal subjects. Metabolism. 1990 Aug; 39(8):827-32.
    View in: PubMed
    Score: 0.006
  34. Hypoglycemic thresholds for cognitive dysfunction in humans. Diabetes. 1990 Jul; 39(7):828-35.
    View in: PubMed
    Score: 0.006
  35. Change in hexose distribution volume and fractional utilization of [18F]-2-deoxy-2-fluoro-D-glucose in brain during acute hypoglycemia in humans. Diabetes. 1990 Feb; 39(2):175-80.
    View in: PubMed
    Score: 0.006
  36. Variation in the perilipin gene (PLIN) affects glucose and lipid metabolism in non-Hispanic white women with and without polycystic ovary syndrome. Diabetes Res Clin Pract. 2009 Dec; 86(3):186-92.
    View in: PubMed
    Score: 0.006
  37. Serum leptin levels in obese males during over- and underfeeding. Obesity (Silver Spring). 2009 Dec; 17(12):2149-54.
    View in: PubMed
    Score: 0.006
  38. Peripheral insulin parallels changes in insulin secretion more closely than C-peptide after bolus intravenous glucose administration. J Clin Endocrinol Metab. 1988 Nov; 67(5):1094-9.
    View in: PubMed
    Score: 0.005
  39. Reduction of insulin clearance during hyperglycemic clamp. Dose-response study in normal humans. Diabetes. 1988 Oct; 37(10):1351-7.
    View in: PubMed
    Score: 0.005
  40. Dose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans. Am J Physiol. 1988 Mar; 254(3 Pt 1):E349-57.
    View in: PubMed
    Score: 0.005
  41. Insulin secretion and clearance. Comparison after oral and intravenous glucose. Diabetes. 1987 Dec; 36(12):1365-71.
    View in: PubMed
    Score: 0.005
  42. Insulin Wakayama: familial mutant insulin syndrome in Japan. Diabetologia. 1987 Feb; 30(2):87-92.
    View in: PubMed
    Score: 0.005
  43. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006 Sep 28; 355(13):1318-30.
    View in: PubMed
    Score: 0.005
  44. Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J Clin Invest. 1986 Jan; 77(1):98-105.
    View in: PubMed
    Score: 0.004
  45. Two-hour seven-sample oral glucose tolerance test and meal protocol: minimal model assessment of beta-cell responsivity and insulin sensitivity in nondiabetic individuals. Diabetes. 2005 Nov; 54(11):3265-73.
    View in: PubMed
    Score: 0.004
  46. Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals. Diabetes. 2005 Aug; 54(8):2447-52.
    View in: PubMed
    Score: 0.004
  47. Insulin sensitivity by oral glucose minimal models: validation against clamp. Am J Physiol Endocrinol Metab. 2005 Dec; 289(6):E954-9.
    View in: PubMed
    Score: 0.004
  48. Glucose counterregulation in patients after pancreatectomy. Comparison with other clinical forms of diabetes. Diabetes. 1984 Nov; 33(11):1112-9.
    View in: PubMed
    Score: 0.004
  49. Portal vein thrombosis complicating islet transplantation in a recipient with the Factor V Leiden mutation. Transplantation. 2004 Jul 15; 78(1):172-3.
    View in: PubMed
    Score: 0.004
  50. C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations. Diabetes. 1984 May; 33(5):486-94.
    View in: PubMed
    Score: 0.004
  51. Plasma somatostatin 28 increases in response to feeding in man. J Clin Invest. 1983 May; 71(5):1514-8.
    View in: PubMed
    Score: 0.004
  52. Responses of somatostatin components to oral glucose in human plasma. Trans Assoc Am Physicians. 1983; 96:113-21.
    View in: PubMed
    Score: 0.004
  53. Relation of counterregulatory responses to hypoglycemia in type I diabetics. N Engl J Med. 1982 Oct 28; 307(18):1106-12.
    View in: PubMed
    Score: 0.004
  54. Diagnosis of acromegaly in a patient with type 1 diabetes mellitus. Endocr Pract. 2002 Mar-Apr; 8(2):113-8.
    View in: PubMed
    Score: 0.003
  55. Insulin release in impaired glucose tolerance: oral minimal model predicts normal sensitivity to glucose but defective response times. Diabetes. 2002 Feb; 51 Suppl 1:S227-33.
    View in: PubMed
    Score: 0.003
  56. GLP-1-induced alterations in the glucose-stimulated insulin secretory dose-response curve. Am J Physiol Endocrinol Metab. 2001 Aug; 281(2):E242-7.
    View in: PubMed
    Score: 0.003
  57. Low acute insulin secretory responses in adult offspring of people with early onset type 2 diabetes. Diabetes. 2001 Aug; 50(8):1828-33.
    View in: PubMed
    Score: 0.003
  58. Dysregulation of insulin secretion in children with congenital hyperinsulinism due to sulfonylurea receptor mutations. Diabetes. 2001 Feb; 50(2):322-8.
    View in: PubMed
    Score: 0.003
  59. Quantitative indexes of beta-cell function during graded up&down glucose infusion from C-peptide minimal models. Am J Physiol Endocrinol Metab. 2001 Jan; 280(1):E2-10.
    View in: PubMed
    Score: 0.003
  60. Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity. Diabetes. 2001 Jan; 50(1):150-8.
    View in: PubMed
    Score: 0.003
  61. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet. 2000 Oct; 26(2):163-75.
    View in: PubMed
    Score: 0.003
  62. Twenty-four-hour leptin levels respond to cumulative short-term energy imbalance and predict subsequent intake. J Clin Endocrinol Metab. 2000 Aug; 85(8):2685-91.
    View in: PubMed
    Score: 0.003
  63. Metabolic effects of short-term elevations of plasma cortisol are more pronounced in the evening than in the morning. J Clin Endocrinol Metab. 1999 Sep; 84(9):3082-92.
    View in: PubMed
    Score: 0.003
  64. Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance. Diabetes. 1998 Aug; 47(8):1259-65.
    View in: PubMed
    Score: 0.003
  65. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998 Feb 01; 128(3):176-85.
    View in: PubMed
    Score: 0.003
  66. Diminished insulin and glucagon secretory responses to arginine in nondiabetic subjects with a mutation in the hepatocyte nuclear factor-4alpha/MODY1 gene. Diabetes. 1997 Nov; 46(11):1749-54.
    View in: PubMed
    Score: 0.003
  67. Evidence that insulin can directly inhibit hepatic glucose production. Diabetologia. 1997 Nov; 40(11):1300-6.
    View in: PubMed
    Score: 0.003
  68. Alterations in the glucose-stimulated insulin secretory dose-response curve and in insulin clearance in nondiabetic insulin-resistant individuals. J Clin Endocrinol Metab. 1997 Jun; 82(6):1834-8.
    View in: PubMed
    Score: 0.002
  69. Transgenic studies with a keratin promoter-driven growth hormone transgene: prospects for gene therapy. Proc Natl Acad Sci U S A. 1997 Jan 07; 94(1):219-26.
    View in: PubMed
    Score: 0.002
  70. Alterations in the ultradian oscillations of insulin secretion and plasma glucose in aging. Diabetologia. 1996 May; 39(5):564-72.
    View in: PubMed
    Score: 0.002
  71. Clinical phenotypes, insulin secretion, and insulin sensitivity in kindreds with maternally inherited diabetes and deafness due to mitochondrial tRNALeu(UUR) gene mutation. Diabetes. 1996 Apr; 45(4):478-87.
    View in: PubMed
    Score: 0.002
  72. Effects of morning cortisol elevation on insulin secretion and glucose regulation in humans. Am J Physiol. 1996 Jan; 270(1 Pt 1):E36-42.
    View in: PubMed
    Score: 0.002
  73. Effects of aging on glucose regulation during wakefulness and sleep. Am J Physiol. 1995 Dec; 269(6 Pt 1):E1006-16.
    View in: PubMed
    Score: 0.002
  74. Brief report: impaired processing of prohormones associated with abnormalities of glucose homeostasis and adrenal function. N Engl J Med. 1995 Nov 23; 333(21):1386-90.
    View in: PubMed
    Score: 0.002
  75. Defects in insulin secretion and action in women with a history of gestational diabetes. Diabetes. 1995 May; 44(5):506-12.
    View in: PubMed
    Score: 0.002
  76. Measurement of proinsulin and intermediates. Validation of immunoassay methods by high-performance liquid chromatography. Diabetes. 1995 Apr; 44(4):437-40.
    View in: PubMed
    Score: 0.002
  77. 24-hour glucose profiles during continuous or oscillatory insulin infusion. Demonstration of the functional significance of ultradian insulin oscillations. J Clin Invest. 1995 Apr; 95(4):1464-71.
    View in: PubMed
    Score: 0.002
  78. Abnormal temporal patterns of glucose tolerance in obesity: relationship to sleep-related growth hormone secretion and circadian cortisol rhythmicity. J Clin Endocrinol Metab. 1994 Dec; 79(6):1797-805.
    View in: PubMed
    Score: 0.002
  79. A new method for comparing portal and peripheral venous insulin delivery in humans: tolbutamide versus insulin infusion. J Clin Endocrinol Metab. 1994 Jul; 79(1):66-70.
    View in: PubMed
    Score: 0.002
  80. Abnormal insulin secretion, not insulin resistance, is the genetic or primary defect of MODY in the RW pedigree. Diabetes. 1994 Jan; 43(1):40-6.
    View in: PubMed
    Score: 0.002
  81. Prior feeding alters the response to the 50-g glucose challenge test in pregnancy. The Staub-Traugott effect revisited. Diabetes Care. 1993 Dec; 16(12):1551-6.
    View in: PubMed
    Score: 0.002
  82. Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1993 Nov; 77(5):1287-93.
    View in: PubMed
    Score: 0.002
  83. Differential effects of glucose stimulation upon rapid pulses and ultradian oscillations of insulin secretion. J Clin Endocrinol Metab. 1993 Apr; 76(4):895-901.
    View in: PubMed
    Score: 0.002
  84. Insulin secretory profiles and C-peptide clearance kinetics at 6 months and 2 years after kidney-pancreas transplantation. Diabetes. 1992 Oct; 41(10):1346-54.
    View in: PubMed
    Score: 0.002
  85. A novel point mutation in the human insulin gene giving rise to hyperproinsulinemia (proinsulin Kyoto). J Clin Invest. 1992 Jun; 89(6):1902-7.
    View in: PubMed
    Score: 0.002
  86. Hypoglycemia due to surreptitious injection of insulin. Identification of insulin species by high-performance liquid chromatography. Diabetes Care. 1991 Jul; 14(7):544-7.
    View in: PubMed
    Score: 0.002
  87. Nocturnal elevation of glucose levels during fasting in noninsulin-dependent diabetes. J Clin Endocrinol Metab. 1991 Feb; 72(2):444-54.
    View in: PubMed
    Score: 0.002
  88. Tumor hypoglycemia: relationship to high molecular weight insulin-like growth factor-II. J Clin Invest. 1990 May; 85(5):1672-9.
    View in: PubMed
    Score: 0.002
  89. Effects of aging on insulin secretion. Diabetes. 1989 Dec; 38(12):1549-56.
    View in: PubMed
    Score: 0.001
  90. Oxygen uptake kinetics during exercise in diabetic neuropathy. J Appl Physiol (1985). 1988 Dec; 65(6):2665-71.
    View in: PubMed
    Score: 0.001
  91. Oscillations in insulin secretion during constant glucose infusion in normal man: relationship to changes in plasma glucose. J Clin Endocrinol Metab. 1988 Aug; 67(2):307-14.
    View in: PubMed
    Score: 0.001
  92. The effect of biosynthetic human proinsulin on the hepatic response to glucagon in insulin-deficient diabetes. J Clin Endocrinol Metab. 1987 Mar; 64(3):476-81.
    View in: PubMed
    Score: 0.001
  93. Proinsulin radioimmunoassay in the evaluation of insulinomas and familial hyperproinsulinemia. Metabolism. 1986 Dec; 35(12):1137-46.
    View in: PubMed
    Score: 0.001
  94. Ingestion of a mixed meal does not affect the metabolic clearance rate of biosynthetic human C-peptide. J Clin Endocrinol Metab. 1986 Aug; 63(2):401-3.
    View in: PubMed
    Score: 0.001
  95. Variable deterioration in cortical function during insulin-induced hypoglycemia. Diabetes. 1985 Jul; 34(7):677-85.
    View in: PubMed
    Score: 0.001
  96. The effects of biosynthetic human proinsulin on carbohydrate metabolism. Diabetes. 1984 Aug; 33(8):762-70.
    View in: PubMed
    Score: 0.001
  97. Familial hyperinsulinemia due to a structurally abnormal insulin. Definition of an emerging new clinical syndrome. N Engl J Med. 1984 May 17; 310(20):1288-94.
    View in: PubMed
    Score: 0.001
  98. Human insulin B24 (Phe----Ser). Secretion and metabolic clearance of the abnormal insulin in man and in a dog model. J Clin Invest. 1984 May; 73(5):1351-8.
    View in: PubMed
    Score: 0.001
  99. Lack of glucagon response to hypoglycemia in type I diabetics after long-term optimal therapy with a continuous subcutaneous insulin infusion pump. Diabetes. 1983 May; 32(5):398-402.
    View in: PubMed
    Score: 0.001
  100. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. N Engl J Med. 1983 Jan 20; 308(3):119-25.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.